Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI Trial

@article{gonzalezmanzanares2026dapagliflozin,
  title = {{Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI Trial}},
  author = {Rafael Gonzalez‐Manzanares and Soledad Ojeda and Ignacio Amat‐Santos and Albert Ariza‐Solé and Rafael Romaguera and Diego López Otero and Luis Nombela‐Franco and Livia Gheorge and Jorge Sanz‐Sánchez and Carlos Baladrón Zorita and Ignacio Gallo and Rafael Cobas Paz and Antonio Jesús Muñoz García and Victoria Vilalta and Gabriela Veiga Fernández and Juan Gabriel Córdoba Soriano and Pedro Cepas‐Gillén and Miriam Sandín Rollán and Xacobe Flores Ríos and Ricardo Palma‐Carbajal and Roberto Martín Reyes and Pablo Avanzas and Sergio García Blas and Juan A. Franco‐Peláez and Javier Martín Moreiras and José Ramón Gonzalez Juanatey and Nieves Gonzalo and German Calle and José Luis Díez and Sandra Santos‐Martínez and Rocío González Ferreiro and Erika Muñoz García and Eduard Fernandez‐Nofrerias and Xoan Sanmartín and Gabriela Tirado and Alejandro Gutierrez Barri and Inmaculada González Bermúdez and Xavier Rosselló and Valentín Fuster and Borja Ibáñez and Sergio Raposeiras Roubín},
  journal = {Journal of the American Heart Association},
  year = {2026},
  month = oct,
  doi = {10.1161/jaha.126.051379},
  url = {https://www.ahajournals.org/doi/10.1161/JAHA.126.051379},
  note = {CC BY-NC},
}

TY  - JOUR
TI  - Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI Trial
AU  - Rafael Gonzalez‐Manzanares
AU  - Soledad Ojeda
AU  - Ignacio Amat‐Santos
AU  - Albert Ariza‐Solé
AU  - Rafael Romaguera
AU  - Diego López Otero
AU  - Luis Nombela‐Franco
AU  - Livia Gheorge
AU  - Jorge Sanz‐Sánchez
AU  - Carlos Baladrón Zorita
AU  - Ignacio Gallo
AU  - Rafael Cobas Paz
AU  - Antonio Jesús Muñoz García
AU  - Victoria Vilalta
AU  - Gabriela Veiga Fernández
AU  - Juan Gabriel Córdoba Soriano
AU  - Pedro Cepas‐Gillén
AU  - Miriam Sandín Rollán
AU  - Xacobe Flores Ríos
AU  - Ricardo Palma‐Carbajal
AU  - Roberto Martín Reyes
AU  - Pablo Avanzas
AU  - Sergio García Blas
AU  - Juan A. Franco‐Peláez
AU  - Javier Martín Moreiras
AU  - José Ramón Gonzalez Juanatey
AU  - Nieves Gonzalo
AU  - German Calle
AU  - José Luis Díez
AU  - Sandra Santos‐Martínez
AU  - Rocío González Ferreiro
AU  - Erika Muñoz García
AU  - Eduard Fernandez‐Nofrerias
AU  - Xoan Sanmartín
AU  - Gabriela Tirado
AU  - Alejandro Gutierrez Barri
AU  - Inmaculada González Bermúdez
AU  - Xavier Rosselló
AU  - Valentín Fuster
AU  - Borja Ibáñez
AU  - Sergio Raposeiras Roubín
PY  - 2026
DA  - 2026/10/20
JO  - Journal of the American Heart Association
DO  - 10.1161/jaha.126.051379
UR  - https://www.ahajournals.org/doi/10.1161/JAHA.126.051379
AB  - Background Frailty is common in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation and portends worse outcomes. Whether the benefit of posttranscatheter aortic valve implantation dapagliflozin differs by frailty is uncertain. Methods In this post hoc analysis, we investigated the efficacy of dapagliflozin according to frailty status in the DapaTAVI (Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation) trial. Frailty was assessed through the Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight scale (robust=0, prefrail=1–2, frail=3–5). The primary outcome was the composite of all‐cause death or worsening heart failure at 1 year. Results Among 1222 patients with baseline frailty assessment, 47.2% were frail, 40.3% prefrail, and 12.4% robust. Over 12 months, 215 patients (17.6%) experienced the primary end point. Patients who were prefrail and frail had higher risk than robust patients (adjusted hazard ratios [HRs], 1.88 [95% CI, 1.05–3.38] and 2.29 [1.29–4.07], respectively; P =0.004). Dapagliflozin was associated with a lower risk of the primary end point in patients who were frail (HR, 0.53 [95% CI, 0.36–0.77]) but not in those who were prefrail (HR, 1.01 [95% CI, 0.66–1.55]) or robust patients (HR, 1.26 [95% CI, 0.42–3.75]); P for interaction=0.021. There was no evidence that frailty modified the safety profile of dapagliflozin. Conclusions Frailty was common and independently associated with worse outcomes after transcatheter aortic valve implantation. Dapagliflozin appeared to confer greater relative benefit in patients with frailty.
SN  - 2047-9980
ER  -